A 68-year-old woman with hypertension on spironolactone and losartan presents with asymptomatic hyperkalemia (K⁺ 6.2 mEq/L). ECG is normal with no peaked T waves or conduction abnormalities. Serum creatinine is 1.8 mg/dL (eGFR ~35 mL/min/1.73 m²), and she is euvolemic. She denies chest pain, palpitations, or dyspnea. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **asymptomatic hyperkalemia** (K⁺ 6.2 mEq/L) with a **normal ECG** — no peaked T waves, no PR prolongation, no QRS widening. She is **euvolemic** with **mild-to-moderate CKD** (eGFR ~35). The hyperkalemia is clearly **iatrogenic**, caused by **dual RAAS blockade** (spironolactone + losartan) in the setting of CKD — a well-recognized and avoidable combination. ## Risk Stratification in Hyperkalemia ```mermaid flowchart TD A[Hyperkalemia K⁺ > 5.5 mEq/L]:::outcome --> B{ECG changes present?}:::decision B -->|Yes: peaked T, PR ↑, QRS ↑| C[EMERGENCY: Calcium + insulin + shift agents]:::urgent B -->|No ECG changes| D{Symptomatic?}:::decision D -->|Palpitations, dyspnea, chest pain| E[Urgent treatment: insulin + shift agents]:::action D -->|Asymptomatic| F{Identifiable reversible cause?}:::decision F -->|Yes: offending drug| G[Discontinue offending agent(s) + recheck K⁺ in 3–5 days]:::action F -->|No reversible cause| H[Cation exchanger ± dietary restriction]:::action ``` ## Why Discontinuing Spironolactone and Losartan Is the Best Next Step **Key Point:** In **asymptomatic hyperkalemia without ECG changes** caused by an identifiable, reversible drug cause, the **most appropriate next step** is to **remove the offending agents** — not to initiate pharmacologic K⁺ removal. 1. **No cardiac emergency** → no need for membrane stabilization (calcium gluconate) 2. **No symptoms** → no need for rapid K⁺ shifting (insulin/dextrose) 3. **Clear iatrogenic cause** → dual RAAS blockade (spironolactone + losartan) is the primary driver; removing both addresses the root cause 4. **Mild-moderate CKD** → impaired K⁺ excretion makes ongoing RAAS blockade particularly dangerous; discontinuation allows renal K⁺ excretion to recover 5. **Rechecking in 3–5 days** is appropriate because K⁺ will trend down once the offending agents are removed | Feature | Discontinue Offending Drugs | Sodium Polystyrene | Insulin + Glucose | Dialysis | |---------|----------------------------|-------------------|-------------------|----------| | **Addresses root cause** | ✓ Yes | ✗ No | ✗ No | ✗ No | | **Appropriate for asymptomatic, no ECG changes** | ✓ First-line | ✗ Adds risk (colonic necrosis) | ✗ Overkill | ✗ Excessive | | **Risk profile** | Low | Moderate (GI adverse effects) | Hypoglycemia risk | High procedural risk | | **Onset of K⁺ lowering** | Hours–days | 4–24 hours | 10–20 minutes | Immediate | ## Why Sodium Polystyrene Sulfonate (Option C) Is NOT the Best Answer Here **Clinical Pearl:** Sodium polystyrene sulfonate (SPS) is a cation-exchange resin that carries significant risks, including **intestinal necrosis** (especially when combined with sorbitol), nausea, and electrolyte disturbances. Current guidelines (Harrison's 21e, KDIGO) recommend **against routine use of SPS** when a reversible cause can be addressed first. In a patient with a clear drug-induced hyperkalemia and no ECG changes, **removing the offending agents is safer and more appropriate** than adding a potentially harmful medication. Furthermore, the **2022 ACC/AHA and KDIGO guidelines** emphasize that in drug-induced hyperkalemia without cardiac manifestations, the priority is **eliminating the causative agent** before initiating pharmacologic K⁺ removal. ## Why Each Option Fails or Succeeds | Option | Appropriateness | Reasoning | |--------|-----------------|----------| | **A: Insulin + glucose now** | ✗ Overkill | Reserved for symptomatic or ECG-positive hyperkalemia; unnecessary here | | **B: Urgent hemodialysis** | ✗ Excessive | Reserved for K⁺ > 7 or refractory/anuric cases; this patient is stable | | **C: Sodium polystyrene TID** | ✗ Not first-line | Carries risk of intestinal necrosis; not indicated when a reversible cause exists | | **D: Discontinue spironolactone + losartan, recheck in 3–5 days** | ✓ Correct | Addresses root cause safely; appropriate for asymptomatic, ECG-normal, drug-induced hyperkalemia | ## Management Summary **Immediate (Today):** - **Discontinue spironolactone** (potassium-sparing diuretic — primary culprit) - **Discontinue losartan** (ARB — contributes to reduced K⁺ excretion in CKD) - Dietary K⁺ restriction (avoid bananas, oranges, tomatoes, potatoes) - Recheck serum potassium in **3–5 days** **Short-term:** - If K⁺ normalizes, consider reintroducing losartan at lower dose with close monitoring (if needed for BP/proteinuria) - Avoid dual RAAS blockade in CKD — this combination is contraindicated per KDIGO guidelines - Monitor renal function and blood pressure **Long-term:** - Consider alternative antihypertensive regimen (e.g., amlodipine, thiazide if eGFR permits) - Monitor K⁺ and creatinine every 3–6 months [cite: Harrison 21e Ch 280; KDIGO CKD Guidelines 2022; KD Tripathi 8e Ch 15]